Brokerages Anticipate Repligen Co. (NASDAQ:RGEN) to Announce $0.72 Earnings Per Share

Wall Street analysts expect that Repligen Co. (NASDAQ:RGENGet Rating) will report earnings per share of $0.72 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Repligen’s earnings. The highest EPS estimate is $0.76 and the lowest is $0.66. Repligen posted earnings of $0.68 per share in the same quarter last year, which suggests a positive year over year growth rate of 5.9%. The business is expected to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Repligen will report full-year earnings of $3.26 per share for the current financial year, with EPS estimates ranging from $3.24 to $3.28. For the next financial year, analysts forecast that the business will post earnings of $3.83 per share, with EPS estimates ranging from $3.60 to $4.12. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Repligen.

Repligen (NASDAQ:RGENGet Rating) last posted its quarterly earnings results on Thursday, February 17th. The biotechnology company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.16. The firm had revenue of $186.52 million during the quarter, compared to analysts’ expectations of $178.27 million. Repligen had a net margin of 19.13% and a return on equity of 10.58%. The firm’s revenue for the quarter was up 71.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share.

RGEN has been the subject of several analyst reports. SVB Leerink cut their price target on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, February 18th. StockNews.com started coverage on shares of Repligen in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 target price for the company. in a report on Monday, February 21st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $291.63.

In other news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System grew its position in shares of Repligen by 2.3% in the first quarter. Louisiana State Employees Retirement System now owns 13,500 shares of the biotechnology company’s stock valued at $2,109,000 after purchasing an additional 300 shares during the last quarter. Strs Ohio boosted its position in Repligen by 17.6% during the first quarter. Strs Ohio now owns 77,600 shares of the biotechnology company’s stock worth $14,595,000 after acquiring an additional 11,600 shares during the last quarter. Redhawk Wealth Advisors Inc. boosted its position in Repligen by 44.8% during the first quarter. Redhawk Wealth Advisors Inc. now owns 6,951 shares of the biotechnology company’s stock worth $1,307,000 after acquiring an additional 2,150 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Repligen by 24.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,713 shares of the biotechnology company’s stock worth $2,015,000 after acquiring an additional 2,139 shares during the last quarter. Finally, Virginia Retirement Systems ET AL boosted its position in Repligen by 21.2% during the first quarter. Virginia Retirement Systems ET AL now owns 8,000 shares of the biotechnology company’s stock worth $1,505,000 after acquiring an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 86.25% of the company’s stock.

NASDAQ RGEN opened at $145.60 on Friday. The stock has a market capitalization of $7.92 billion, a P/E ratio of 65.00 and a beta of 0.90. Repligen has a 52-week low of $145.45 and a 52-week high of $327.32. The firm has a 50-day moving average price of $176.27 and a 200 day moving average price of $221.48.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.